Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Nigeria has become the first country to receive the new MenFive meningitis vaccine
This was revealed in a statement by Gavi on Thursday.
The vaccine doses will be used to respond to an ongoing meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa state where there has been more cases.
MenFive vaccine, was developed through a 13-year collaboration between PATH and Serum Institute of India and received WHO prequalification in July 2023.
Meningitis follows a seasonal pattern, mostly common during the dry season December through June with a peak between March and April when there is persistent low air humidity and high dust loads that are believed to damage the pharyngeal mucosa and ease the colonization of the nasopharyngeal epithelium by the meningococci.
This vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa.
The African meningitis belt stretches from Senegal in the west to Ethiopia in the east in 26 countries, including the northern part of Nigeria.
Related posts:
Nigeria to get additional 820,000 Meningitis C vaccine from UK – WHO
Nigeria becomes 2nd African country to host World Toilet Summit
Nigeria becomes first African Country to consider Wildlife contingency plan
Nigeria becomes first African country to adopt ISSB’s sustainability standards
UK becomes first country to approve antiviral pill for treatment of COVID-19
Zambia becomes third country to implement VAR technology
Nigeria to receive Covid-19 Vaccine on Tuesday – SGF
Nigeria did not receive batch of AstraZeneca vaccine linked to blood clot – NPHCDA
